personalized medicine

  •  

    Raising AI Right: Prioritizing Humanity in Precision Medicine

    With: Michael Kramer

    Artificial intelligence (AI) holds promise to transform cancer research and treatment. Here, Curious Dr. George asks our very own Director of Technology, Michael Kramer, about the powerful role Cancer Commons can play in shaping the future of AI in oncology. Having lost his son, Theo, to a rare form of brain cancer—Diffuse Intrinsic Pontine Glioma (DIPG)—Kramer is deeply committed to helping others facing similar… Read more »

  •  

    Cancer Commons: Breaking Barriers in Cancer Care

    With: DeLeys Brandman, MD

    For more than a decade, Cancer Commons has helped patients and their care teams access the information and data they need to make informed decisions. Demand for this kind of help is only growing. Here, Curious Dr. George asks our very own Medical Director, DeLeys Brandman, MD, about her vision for expanding Cancer Commons’ services to help many more patients. In addition to her… Read more »

  •  

    A Better Way to Keep an Eye on Glioblastoma Tumors

    With: Michael Schmainda, MBA

    For people with glioblastoma brain tumors, it can be vital yet challenging to determine the precise size, location, and extent of the tumor. A company called Imaging Biometrics, LLC, has developed novel imaging strategies to address this issue. Here, our Curious Dr. George asks its president and CEO Michael Schmainda about these innovations. Curious Dr. George: Determining the extent of an intracranial neoplasm can be… Read more »

  •  

    The Personalized Power of the “N-of-1” Approach

    With: Glenn Sabin

    Randomized, controlled clinical trials with a large N—number of participants—are the recognized “gold standard” of evidence-based medicine. Even so, the results of large-N trials can only reveal population averages, and are not predictive of any individual’s response to a given treatment. On the other hand, one can consider every patient with cancer as the sole participant in their own clinical trial with an Nof1, even if the trial is not… Read more »

  •  

    SAGE Oncotest: Entering the Next Generation of Tailored Cancer Treatment

    With: Chris Apfel, MD, PhD, MBA

    For people with recurring or drug-resistant cancer, choosing the best-possible next treatment can pose a huge challenge. Our Curious Dr. George asks Chris Apfel, MD, PhD, MBA—Founder, CEO, and Board Chair of SageMedic Corp.—about his company’s solution for many of these patients. Curious Dr. George: Despite the application of curative surgical, radiation, and systemic treatments, cancer remains the “emperor of all maladies” with 600,000… Read more »

  •  

    Protean BioDiagnostics: One Way to Access Full-Service Precision Oncology Testing

    With: Anthony M. Magliocco, MD

    The use of advanced molecular testing of various cancers over the last 10-15 years has driven development of the field of precision oncology. Now, many patients with a variety of cancer types can benefit from targeted therapies. However, accessing precision testing and treatment can be a major challenge. Our Curious Dr. George asks Anthony M. Magliocco, MD, Founder and CEO of Protean BioDiagnostics, how his company… Read more »

  •  

    Alibrex: A New Blood Test to Reveal Whether a Cancer Treatment is Working

    With: Kevin Knopf, MD, MPH

    In cancer treatment, time is of the essence. Our Curious Dr. George asks Kevin B. Knopf, MD, MPH, Chief Medical Officer at Cadex Genomics, how his company’s new test, Alibrex, could rapidly reveal how well a given treatment is working for a given patient. Curious Dr. George: The U.S. Food and Drug Administration has approved about 270 anti-cancer drugs. The National Comprehensive Cancer Network… Read more »

  •  

    Common Sense Oncology: Moving Back Towards Outcomes that Matter

    With: Christopher M. Booth, MD, FRCPC

    There are many ways to measure how well a particular cancer treatment works. But how much do these outcomes reflect a patient’s actual wellbeing? Our Curious Dr. George asks Christopher M. Booth, MD, FRCPC, one of the founding leaders of the new international initiative “Common Sense Oncology” (CSO), how CSO is working to improve patient outcomes. Curious Dr. George: The practice of clinical oncology… Read more »

  •  

    PARIS Test Uses Lab-Grown Mini-Tumors to Find a Patient’s Best Treatment

    With: Carla Grandori, MD, PhD

    The U.S. Food and Drug Administration (FDA) has approved hundreds of drugs for the treatment of cancer. However, some approved drugs are more effective for certain patients than others. Our curious Dr. George asks Carla Grandori, MD, PhD, Founder and CEO of SEngine Precision Medicine, about her company’s test to detect which drugs are likely to be most effective for a given patient’s solid tumor.… Read more »

  •  

    A New Biomarker to Optimize Immunotherapy for People with Cancer

    With: Scott Tomlins, MD, PhD

    Immunotherapy—a type of treatment that harnesses a patient’s own immune system to fight cancer—has been a “game changer” for many patients. It can be difficult, however, to predict whether or not a given person would benefit from immunotherapy, especially when it comes to drugs that target the immune system molecules PD-1 and PD-L1. Our Curious Dr. George asks Scott Tomlins, MD, PhD, Co-founder and… Read more »